Product Description
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer|Non-Small-Cell Lung Cancer
Phase 1: Breast Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Healthy Volunteers|Lymphoma, Non-Hodgkin|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2012-003262-41 | P2 |
Completed |
Breast Cancer |
2016-10-16 |
|
| 2010-023763-17 | P2 |
Completed |
Breast Cancer |
2016-04-07 |
|
| GDC4950g | P2 |
Completed |
Breast Cancer |
2016-04-01 |
|
| JapicCTI-132162 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2016-03-31 |